Key Drivers
- Strong liquidity
- Persistent cash burn
- Negative equity
AIAI Summary
CYTK has shifted from a binary biotech bet to an early commercial cardiology story with approved aficamten and visible launch traction, but with only $4.8M in Q1 revenue versus roughly $145M of quarterly cash burn, negative equity, and ~90x sales valuation, the stock now depends on rapid U.S./global adoption outpacing dilution and balance-sheet pressure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent cash burn
- •Negative equity
CYTK has ample short-term liquidity and strong gross margins, but heavy losses, persistent cash burn, negative equity, and a rich valuation make the stock fundamentally risky.
Price Behavior
Key Price Behavior Insights:
- •Strong rebound
- •Mid-$80s support
- •Overbought stretch
CYTK remains in a constructive uptrend over the last month after a strong rebound from the high-$60s to the high-$80s, but it is now stretched and must hold the mid-$80s to avoid a short-term pullback.
Rapid climb from about $67 to the mid-$80s over the last month raises pullback risk
Sentiment & News
Key News Insights:
- •Myqorzo launch
- •Hiring incentives
- •Investor outreach
Cytokinetics is showing launch-driven momentum and active corporate engagement, with Myqorzo's FDA approval supporting stock gains while inducement grants, community giving, and conference حضور reinforce ongoing execution.
These updates are mildly positive for CYTK, reinforcing commercialization progress and management's focus on retention and market visibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings